tiprankstipranks
Trending News
More News >

Altimmune’s Pemvi hits MASH goal, shows broad potential, says Stifel

Altimmune (ALT) released 24-week Phase 2b data for pemvidutide in metabolic dysfunction-associated steatohepatitis showing it met the primary endpoint of statistically significant MASH resolution, Stifel analyst Annabel Samimy tells investors in a research note. It also showed promising trends in fibrosis improvement, 5.2% weight loss with no plateau, and strong tolerability, the firm says With these results, Pemvi stands out as a potent, fast-acting GLP-1/GCG agonist that could serve as a single-treatment option for both MASH and obesity. Stifel has a Buy rating and $18 price target on Altimmune shares.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1